Overview
- Regulatory and clinical moves this year, including approval of an oral GLP‑1 pill, have strengthened the shift from injectable diabetes drugs to widely used metabolic and weight‑loss therapies.
- Market research projects the class will more than quadruple in value by 2034 as rising obesity and new oral options expand demand for semaglutide-, tirzepatide- and next‑generation products.
- Employers and health plans are responding to rapid uptake by raising cost‑sharing, adding utilization controls, and requiring specialty‑provider or weight‑management program rules to limit pharmacy spending.
- Regulators and clinicians have flagged safety concerns such as reported suicidal thoughts, contraceptive interactions, delayed gastric emptying with surgical aspiration risk, and muscle and bone loss from rapid weight loss, prompting calls for structured multidisciplinary care.
- Clinical trials show many patients regain weight after stopping treatment but that lower‑dose maintenance or switching to oral formulations can help preserve loss, which may make long‑term therapy and wraparound services the new standard of care for many patients.